[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612563":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":11,"studyPopulation":11,"armGroups":28,"interventions":42,"overallOfficials":11,"centralContacts":51,"locations":57,"responsibleParty":80,"collaborators":11,"id":82,"slug":11,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":11,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":11,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":11,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Innovent Biologics (Suzhou) Co. Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percent Change from Baseline in BMI",null,"Week 32",[14,16,18],{"measure":15,"description":11,"timeFrame":12},"Percentage of Participants with ≥5% BMI Reduction",{"measure":10,"description":11,"timeFrame":17},"Week 52",{"measure":15,"description":11,"timeFrame":17},{"allocation":20,"interventionModel":21,"interventionModelDescription":11,"primaryPurpose":22,"observationalModel":11,"timePerspective":11,"maskingInfo":23},"RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":24,"maskingDescription":11,"whoMasked":25},"DOUBLE",[26,27],"PARTICIPANT","INVESTIGATOR",[29,34,39],{"label":30,"type":31,"description":11,"interventionNames":32},"Placebo","PLACEBO_COMPARATOR",[33],"Drug: Placebo",{"label":35,"type":36,"description":11,"interventionNames":37},"IBI362-dose2","EXPERIMENTAL",[38],"Drug: IBI362",{"label":40,"type":36,"description":11,"interventionNames":41},"IBI362-dose1",[38],[43,47],{"type":44,"name":30,"description":45,"armGroupLabels":46,"otherNames":11},"DRUG","Placebo SA.QW",[30],{"type":44,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"IBI362","IBI362 SA.QW",[40,35],[52],{"name":53,"role":54,"phone":55,"phoneExt":11,"email":56},"Xiaoyan li","CONTACT","18756032014","xiaoyan.li@innoventbio.com",[58],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"The Children's Hospital, Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310052","China","CN",{"type":67,"coordinates":68},"Point",[69,70],120.16142,30.29365,{"lat":70,"lon":69},[73,77],{"name":74,"role":54,"phone":75,"phoneExt":11,"email":76},"Junfen Fu","13777457849","fjf68@zju.edu.cn",{"name":78,"role":79,"phone":11,"phoneExt":11,"email":11},"Junfen Fu, M.D","PRINCIPAL_INVESTIGATOR",{"type":81,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100612563",false,"NCT07255209","A Study of IBI362 in Chinese Adolescents With Obesity or Overweight","A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）","Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to be enrolled:\n\nKey Inclusion Criteria：\n\n1. Male or female participants aged ≥12 years and \\\u003C18 years at the time of signing the informed consent\u002Fassent form.\n2. BMI at screening meeting the obesity criteria defined by \"WS\u002FT 586-2018 Screening for Overweight and Obesity in School-Age Children and Adolescents\" or meeting overweight criteria plus at least one weight-related comorbidity: prediabetes, type 2 diabetes, hypertension, dyslipidemia, fatty liver disease, or obstructive sleep apnea syndrome.\n3. Weight change \\\u003C5 kg after ≥12 weeks of diet and exercise alone before screening (per self\u002Fparental report).\n\nExclusion Criteria:\n\nKey Exclusion Criteria：\n\n1. Prior diagnosis of type 1 diabetes.\n2. Pre-pubertal participants (Tanner Stage I).\n3. History of (or planned) bariatric surgery (except liposuction\u002Fabdominoplasty or acupuncture for weight loss performed \\>1 year before screening).","ALL","12 Years","18 Years",{"count":92,"type":93},180,"ESTIMATED","INTERVENTIONAL",[96],"PHASE3","The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \\\u003C18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.",[99],"Adolescents With Obesity or Overweight With Weight-Related Comorbidities","2026-01-07",{"date":102,"type":103},"2026-01-08","ACTUAL",{"date":105,"type":103},"2025-12-29",{"date":107,"type":93},"2028-10-31",{"name":5,"class":6},1]